Argenx
ARGX
$374.63
Share price
-2.07%
Change (1 day)
-6.89%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Argenx (ARGX) - Total debt
Total debt on the balance sheet as of December 2023 : $20 M
According to Argenx 's latest financial reports the company's total debt is $20 M. A company’s total debt is the sum of all current and non-current debts.
Argenx - Total debt on balance sheet (from 2017 to 2020)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $12.42 M | 8.38% |
| 2021-12-31 | $11.46 M | -3.48% |
| 2020-12-31 | $11.87 M | 44.87% |
| 2019-12-31 | $8.19 M | |
| 2018-12-31 | $N/A | |
| 2017-12-31 | $N/A | |
| 2013-12-31 | $N/A | -100% |
| 2012-12-31 | $2.95 M | 4.14% |
| 2011-12-31 | $2.84 M |